Thompson Street Capital Partners (TSCP), a private equity firm based in St. Louis, today announced its portfolio company Isto Biologics, a leader in surgical-based, osteo-biologic regeneration technologies and cell-based therapies, has acquired TheraCell, Inc., a California-based regenerative medicine company. The acquisition will strengthen Isto’s focus on offering extraordinary solutions for surgical and clinical care procedures within spine, orthopedics, and sports medicine. Terms of the transaction were not disclosed.
“We are thrilled to add TheraCell’s unmatched technology to our market leading biologics portfolio,” said Don Brown, CEO of Isto Biologics. “TheraCell has excelled in developing advanced bone integrating, anchoring, and bridging technologies for spinal repair for over a decade.”
The acquisition will expand Isto Biologics’ growing portfolio of orthopedic grafts and introduce TheraCell’s proprietary and patented TheraFuze DBF® technology that will become part of Isto Biologics’ Influx™ line.
“Isto is the leader in allo-derived spine solutions. They have an incredible patient-centric, outcomes-focused commercial and clinical team that will rapidly accelerate the surgical adoption of the technology that we’ve always been passionate about,” added Bradley Patt, CEO of TheraCell.
“Both Isto Biologics and TheraCell have achieved success in developing and introducing innovative, first-of-their-kind product offerings to help patients heal faster,” said Harry Holiday, Chairman of the Board at Isto Biologics and Managing Director at TSCP. “Adding TheraCell’s product portfolio to Isto’s top-tier sales team will add tremendous value to TheraCell’s place in the market. We anticipate an unparalleled synergy by combining these two great organizations.
